AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing ...Middle East

Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Patented Flagship NB-A002 is a First-in-class DNA...

Hence then, the article about ai drug discovery pioneer nanyang biologics pte ltd enters into business combination agreement with rf acquisition corp ii in us 1 5b transaction to pursue public listing was published today ( Thursday 02/10/2025 - 02:55 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing )

Also on site :

• Pakistan-Afghanistan Fued Freezes $3 Billion in Annual Bilateral Trade
• ANGHAMI REPORTS H1 2025 FINANCIAL RESULTS; MARKED BY TOPLINE GROWTH AND TRANSFORMATIVE DEAL WITH WARNER BROS. DISCOVERY
• Argentina’s Shale Boom Propels It Past Colombia in Oil Output